The U.S. Food and Drug Administration (FDA) is requiring new warnings about a rare but potentially permanent form of vision loss associated with Ozempic, Wegovy, and other GLP-1 medications commonly prescribed for diabetes and weight management.
On November 9, 2026, the FDA announced new safety labeling requirements after reviewing evidence suggesting these medications may increase the risk of non-arteritic anterior ischemic optic neuropathy (NAION), a condition that damages the optic nerve and can cause sudden vision loss.
The decision affects an entire class of widely used medications and comes amid ongoing lawsuits alleging that drug manufacturers failed to adequately warn patients about potential vision injuries.
GLP-1 Medications Affected by the FDA Warning
The FDA is directing manufacturers to add information about the potential risk of NAION to the Warnings and Precautions section of GLP-1 receptor agonist drug labels.
Affected medications include:
- Ozempic, Wegovy, and Rybelsus (semaglutide)
- Mounjaro and Zepbound (tirzepatide)
- Trulicity (dulaglutide)
- Victoza and Saxenda (liraglutide)
Other medications in the GLP-1 drug class are also covered by the labeling requirement.
These drugs work by mimicking hormones involved in blood sugar regulation and appetite control. While they offer important benefits for many patients, the FDA’s decision reflects growing evidence of a possible connection between GLP-1 medications and serious optic nerve injuries.
What Is NAION? Can It Cause Permanent Vision Loss?
Non-arteritic anterior ischemic optic neuropathy occurs when blood flow to the front portion of the optic nerve is reduced, damaging the nerve that transmits visual information to the brain. NAION typically causes sudden, painless vision loss in one eye. Some people first notice symptoms when they wake up.
Warning signs can include:
- Sudden loss or blurring of vision in one eye
- Blind spots or missing portions of the visual field
- Reduced central vision
- Changes in color perception
- Tunnel vision or other visual disturbances
Vision loss from NAION can be permanent, and there’s currently no established treatment that reliably reverses the damage.
Diabetes, high blood pressure, sleep apnea, and certain other medical conditions can also increase a person’s risk of developing NAION. This makes it difficult to determine whether a particular case was caused by medication use or another underlying factor.
Research Behind the FDA’s New NAION Warning
The FDA reviewed clinical trials, observational research, and adverse event reports before deciding that additional warnings were warranted. One analysis included 126 randomized clinical trials involving more than 134,000 patients. Researchers found:
- 6.4 NAION cases per 100,000 person-years among patients receiving GLP-1 medications.
- 3.8 NAION cases per 100,000 person-years among patients receiving comparison treatments.
These findings suggest a small increase in the absolute risk of NAION among GLP-1 users, although the condition remains rare.
The agency also reviewed real-world medical data and published research, including a 2024 JAMA Ophthalmology study that raised concerns about NAION among patients prescribed semaglutide.
Not all studies produced identical findings, and researchers have not established exactly how GLP-1 medications might contribute to optic nerve damage.
The FDA concluded that the available evidence supports warning patients and healthcare professionals about a potential increased risk, rather than establishing that these drugs directly cause NAION in every reported case.
What Should Patients Taking Ozempic or Other GLP-1 Drugs Do?
The FDA is encouraging patients to watch for possible vision changes while taking GLP-1 medications. Anyone who experiences sudden vision loss, new blind spots, or other significant visual disturbances should seek immediate medical attention. Prompt evaluation by an ophthalmologist is important because sudden vision loss can have several serious causes.
Patients who have experienced NAION should speak with their healthcare provider about whether to continue taking their GLP-1 medication.
The new warning doesn’t mean everyone taking Ozempic, Wegovy, or similar drugs should stop treatment. Patients should discuss their individual risks, medical history, and treatment options with their prescribing physician before changing their medication.
Ozempic Vision Loss Lawsuits Continue as FDA Updates Warnings
The FDA’s decision also comes as lawsuits involving Ozempic, Wegovy, and alleged vision injuries move through federal court.
Patients who developed NAION after using certain GLP-1 medications have filed product liability lawsuits alleging that manufacturers failed to adequately disclose the potential risk of permanent vision loss.
These cases raise questions about what drug manufacturers knew about possible eye injuries, when that information became available, and whether patients and healthcare providers received adequate warnings. The FDA’s labeling decision may become relevant to the litigation, but it doesn’t establish that a manufacturer is legally responsible for an individual patient’s injury.
The FDA’s new warning highlights the importance of continued monitoring of prescription drug safety, particularly as GLP-1 medications become more widely used. Childers, Schlueter & Smith (CSS) follows developments involving pharmaceutical injuries, drug safety warnings, and dangerous drug lawsuits that raise questions about manufacturers’ responsibility to warn patients of potential risks.
If you or a loved one has suffered a serious injury involving a prescription medication, contact CSS or call 1-800-641-0098 to discuss your concerns and learn more about your legal options.
Other Dangerous Drugs News
Research suggests Dupixent (dupilumab) may be linked to an increased risk of cutaneous T-cell lymphoma (CTCL). Learn what studies show, how CTCL may be misdiagnosed as eczema, and the legal options for patients diagnosed with lymphoma after taking Dupixent.
Childers, Schlueter & Smith has filed the first Dupixent lawsuit in Georgia, alleging a link between the eczema drug and cutaneous T-cell lymphoma (CTCL). The complaint highlights questions about risk disclosure.
A recent FDA-approved label change now warns of brain meningioma risks linked to Depo-Provera. This update explains what changed, why lawsuits are being filed, and what the warning may mean for women diagnosed with brain tumors.
While Suboxone helps fight opioid addiction, it’s now at the center of a growing legal battle over severe, preventable dental harm not disclosed to patients for years.
Women across the U.S. are filing lawsuits against Pfizer after a major study linked long-term use of Depo-Provera to a fivefold increase in the risk of developing brain tumors known as meningiomas.
Women diagnosed with meningiomas after using Depo-Provera may be eligible for financial compensation, as lawsuits claim Pfizer failed to warn about the potential risk of brain tumors.







